{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T23:05:34Z","timestamp":1771369534728,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.clinthera.2006.11.009","type":"journal-article","created":{"date-parts":[[2007,1,8]],"date-time":"2007-01-08T09:59:32Z","timestamp":1168250372000},"page":"1827-1836","source":"Crossref","is-referenced-by-count":38,"title":["Cardiovascular events associated with the use of four nonselective NSAIDs (Etodolac, Nabumetone, Ibuprofen, or Naproxen) Versus a Cyclooxygenase-2 Inhibitor (Celecoxib): A population-based analysis in taiwanese adults"],"prefix":"10.1016","volume":"28","author":[{"given":"Weng-Foung","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-Yuan","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Wen","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-Wen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.11.009_bib1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2006.11.009_bib2","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1213\/01.ANE.0000061461.55712.C5","article-title":"Cyclooxygenase-2 inhibitors","volume":"96","author":"Gajraj","year":"2003","journal-title":"Anesth Analg."},{"key":"10.1016\/j.clinthera.2006.11.009_bib3","first-page":"19","article-title":"Rofecoxib, celecoxib, and cardiovascular risks","volume":"22","author":"Adverse Drug Reactions Advisory Committee","year":"2003","journal-title":"Aust Adv Drug Reactions Bull"},{"key":"10.1016\/j.clinthera.2006.11.009_bib4","first-page":"S287","article-title":"Risk of acute cardiac events among patients treated with cyclooxygenase-2 selective and non-selective nonsteroidal anti-inflammatory drugs [abstract]","volume":"13","author":"Graham","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.clinthera.2006.11.009_bib5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(02)11131-7","article-title":"COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease","volume":"360","author":"Ray","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.11.009_bib6","first-page":"642","article-title":"Hypertension in the patient with arthritis: Have we been underestimating its significance?","volume":"30","author":"Day","year":"2003","journal-title":"J Rheumatol."},{"key":"10.1016\/j.clinthera.2006.11.009_bib7","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1056\/NEJMc045711","article-title":"Cardiovascular toxicity of valdecoxib","volume":"351","author":"Ray","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.11.009_bib8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)16894-3","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: Randomised controlled trial","volume":"364","author":"Farkouh","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.11.009_bib9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.7326\/0003-4819-142-3-200502010-00013","article-title":"Cardiovascular risks of cyclooxygenase-2 inhibitors: Where we stand now","volume":"142","author":"Finckh","year":"2005","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.clinthera.2006.11.009_bib10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2165\/00002018-200528080-00001","article-title":"What are the real lessons from Vioxx?","volume":"28","author":"Edwards","year":"2005","journal-title":"Drug Saf."},{"key":"10.1016\/j.clinthera.2006.11.009_bib11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jama.293.3.366","article-title":"Arthritis medicines and cardiovascular events\u2014\u201chouse of coxibs\u201d","volume":"293","author":"Topol","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.11.009_bib12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(04)16906-7","article-title":"A coxib a day won't keep the doctor away","volume":"364","author":"Topol","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.11.009_bib13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/jama.293.4.413","article-title":"Experts point to lessons learned from controversy over rofecoxib safety","volume":"293","author":"Hampton","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.11.009_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00002018-200528030-00001","article-title":"Do selective cyclo-oxygenease-2 inhibitors have a future?","volume":"28","author":"Bannwarth","year":"2005","journal-title":"Drug Saf."},{"key":"10.1016\/j.clinthera.2006.11.009_bib15","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.293.13.1571","article-title":"FDA panel: Keep COX-2 drugs on market: Black box for COX-2 labels, caution urged for all NSAIDs","volume":"293","author":"Kuehn","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.11.009_bib16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1001\/jama.293.6.664","article-title":"Officials halt NSAID prevention trials","volume":"293","author":"Hampton","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.11.009_bib17","series-title":"Analysis and recommendations for agency action-COX-2 selective and nonselective NSAIDs","author":"US Food and Drug Administration","year":"2005"},{"key":"10.1016\/j.clinthera.2006.11.009_bib18","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.11.009_bib19","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofe coxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.11.009_bib20","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa050330","article-title":"Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery","volume":"352","author":"Nussmeier","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.11.009_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archinte.165.2.181","article-title":"Selective cyclooxygenase-2 inhibition and cardiovascular effects: An observational study of a Medicaid population","volume":"165","author":"Shaya","year":"2005","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.clinthera.2006.11.009_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-142-3-200502010-00005","article-title":"Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction","volume":"142","author":"Kimmel","year":"2005","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.clinthera.2006.11.009_bib23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(05)17864-7","article-title":"Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study","volume":"365","author":"Graham","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.11.009_bib24","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/rheumatology\/keh610","article-title":"Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis","volume":"44","author":"Bernatsky","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2006.11.009_bib25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00002018-200528050-00006","article-title":"Incidence ofthrombotic cardiovascular events in pa tients taking celecoxib compared with those taking rofecoxib: Interim results from the New Zealand Intensive Medicines Monitoring Programme","volume":"28","author":"Harrison-Woolrych","year":"2005","journal-title":"Drug Saf."},{"key":"10.1016\/j.clinthera.2006.11.009_bib26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00002018-200528090-00005","article-title":"A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data","volume":"28","author":"Kasliwal","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2006.11.009_bib27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00002018-200629030-00009","article-title":"Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: An observational study","volume":"29","author":"Huang","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.clinthera.2006.11.009_bib28","article-title":"Centers for Disease Control and Prevention, National Center for Health Statistics (NCHS)","author":"US Dept of Health and Human Services","year":"2003"},{"key":"10.1016\/j.clinthera.2006.11.009_bib29","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1056\/NEJMp048286","article-title":"Failing the public healthrofecoxib, Merck, and the FDA","volume":"351","author":"Topol","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.11.009_bib30","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMe058038","article-title":"COX-2 inhibitors-a lesson in unexpected problems","volume":"352","author":"Drazen","year":"2005","journal-title":"N Engl J Med."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806002797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806002797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:52:28Z","timestamp":1547081548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806002797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0149291806002797"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.11.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}